This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by el Amin, N.
Right arrow Articles by Wretlind, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by el Amin, N.
Right arrow Articles by Wretlind, B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1999, p. 947-949, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Alterations in GyrA and ParC Associated with Fluoroquinolone Resistance in Enterococcus faecium

Nagwa el Amin, Shah Jalal, and Bengt Wretlind*

Division of Clinical and Oral Bacteriology, Department of Immunology, Microbiology, Pathology, and Infectious Diseases, Huddinge University Hospital, S-14186 Huddinge, Sweden

Received 5 October 1998/Returned for modification 10 November 1998/Accepted 28 January 1999


    ABSTRACT
Top
Abstract
Text
References

High-level quinolone resistance in Enterococcus faecium was associated with mutations in both gyrA and parC genes in 10 of 11 resistant strains. One low-level resistant strain without such mutations may instead possess an efflux mechanism or alterations in the other subunits of the gyrase or topoisomerase IV genes. These findings are similar to those for other gram-positive bacteria, such as Enterococcus faecalis.


    TEXT
Top
Abstract
Text
References

Enterococci are important pathogens and a common cause of serious nosocomial infections such as bacteremia and endocarditis (21). Enterococcus faecalis is the most common isolate among enterococci. However, Enterococcus faecium has become increasingly important after the emergence of ampicillin and vancomycin resistance. Clinical isolates resistant to vancomycin are usually resistant to quinolones and almost all currently available antibiotics (1, 2, 10), but new fluoroquinolones may still have therapeutic value for enterococcal infections (12). At Huddinge Hospital, where this study was conducted, the frequency of quinolone-resistant enterococci has increased from 11% in 1994 to 25% in 1997.

Recent studies showed that fluoroquinolone resistance in gram-negative organisms is associated with mutations in the gyrA gene (subunit of DNA gyrase) or with a reduced accumulation of the drug (3, 9, 18, 22, 23, 29, 30). In gram-positive bacteria, fluoroquinolone resistance can be associated with mutations in the gyrA or parC (subunit of topoisomerase IV) gene (6, 7, 16, 17, 19, 26), and in some gram-positive organisms, such as Staphylococcus aureus, efflux pumps have been identified (6, 7, 13, 16, 17, 19, 26, 31).

The nucleotide sequence encoding 41 amino acids in the gyrase A protein, corresponding to Escherichia coli amino acids 67 to 106 in the GyrA protein (5, 8, 25, 27, 28), was identified in both gram-negative and gram-positive organisms as the quinolone resistance determining region.

In this study we have analyzed clinical quinolone-resistant E. faecium isolates for mutations in the genes encoding subunits of the quinolone target enzymes GyrA and ParC. Twelve clinical isolates of E. faecium, collected in different Swedish hospitals, were studied. The isolates were identified by using API 20 STREP (bioMérieux, Marcy l'Etoile, France). The MICs of ciprofloxacin and trovafloxacin were determined by using the E test (Biodisk, Solna, Sweden) on Iso-Sensitest agar (Oxoid) or, for those strains for which MICs of ciprofloxacin were >= 32 µg/ml, the agar dilution method on PDM-ASM agar (Biodisk) with 5% horse blood (4). The antibiotic susceptibilities are shown in Table 1. Of the 12 isolates, 10 were resistant (here defined as any strain for which the MIC of ciprofloxacin is >8 µg/ml), one was susceptible, and for another the MICs of both drugs were slightly higher than for the reference strain. The type strain E. faecium ATCC 19434 was used as a reference.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Alterations in gyrA and parC genes in clinical isolates of E. faceium

Genomic DNA was extracted from the 11 isolates and the type strain, by using the guanidium thiocyanate method (24). The target regions were amplified by using PCR with primers derived from E. faecalis sequences. A DNA fragment of 241 bp from the gyrA gene corresponding to the quinolone resistance determining region was amplified with the 23-mer oligonucleotide primers 5'-CGG GAT GAA CGA ATT GGG TGT GA-3' and 5'-AAT TTT ACT CAT ACG TGC TTC GG-3', equivalent to nucleotide positions 150 to 172 and 368 to 390 of the E. coli gyrA gene (15), respectively, and a 191-bp parC fragment was amplified with the 20-mer oligonucleotide primers 5'-AAT GAA TAA AGA TGG CAA TA-3' and 5'-CGC CAT CCA TAC TTC CGT TG-3' (positions 10 to 29 and 181 to 200 of the E. faecalis parC gene, respectively) (14). One-step PCR was performed for each gene in a 50-µl reaction mixture containing 1.25 U of Taq DNA polymerase, 200 µM concentrations of each deoxynucleoside triphosphate, 45 pmol of each primer, 1.5 mM MgCl2, and 10× PCR buffer (Sigma). Each reaction was run for 30 cycles with the following temperature profile: denaturation at 94°C for 1 min, annealing at 55°C for gyrA and 48.7°C for parC for 1 min, and then extension at 72°C for 1 min. The amplified fragments were processed for cycle sequencing by using the ABI PRISM Big-dye terminator kit, and sequences were then analyzed by capillary electrophoresis in an ABI PRISM 310 automated sequencer. Analysis for alteration in target position was carried out as described by Jalal and Wretlind (11).

The nucleotide sequences of 195 bp of gyrA between the primers and 151 bp of parC between the primers were then determined and analyzed for alterations at the key amino acid positions. The E. faecium GyrA partial amino acid sequence showed 97, 88, and 63% identities with E. faecalis, Streptococcus pneumoniae, and E. coli, respectively. The corresponding identities for ParC were 92, 78, and 47% (Fig. 1).


View larger version (11K):
[in this window]
[in a new window]
  		FIG. 1.   E. faecium (Efem) GyrA (A) and ParC (B) partial gene sequences, compared with those of E. faecalis (Efecl), S. pneumoniae (Spn), and E. coli. The numbered amino acids start from the first amino acid in the complete sequence of E. coli and in partial sequences of the others. Only amino acids that differ from those of E. faecium are shown. Asterisks mark the mutation points.

In 10 of the strains GyrA showed single amino acid changes relative to strain ATCC 19434. The serine at position 83 (corresponding to E. coli) was changed to tyrosine in three strains, to isoleucine in one strain, and to arginine in another. At position 87, glutamate was changed to lysine in five isolates. In the parC gene, a single amino acid change was encoded, the serine at position 80 (corresponding to E. coli) to isoleucine in 10 strains (Table 1). One susceptible strain and one strain for which the MIC of ciprofloxacin was 8 µg/ml and that of trovafloxacin was 4 µg/ml had no alterations in gyrA or parC.

Two nucleotide substitutions were needed for the alteration of serine (AGT) to tyrosine (TAT). One possible explanation is that the parent strains had serine (TCT) in this position. Kanematsu et al. (14) found similar mutations with two nucleotide changes in E. faecalis at position 80 of the parC gene, where serine (AGT) was changed to arginine (CGC) in one strain and to isoleucine (ATC) in nine strains. Some of the strains in this study showed the same mutations in both gyrA and parC despite the fourfold difference in MICs of ciprofloxacin or trovafloxacin (Table 1). The most resistant strains may also have efflux systems and/or mutations in gyrB or parE.

Kanematsu et al. (14) found similar mutations in the gyrA and parC genes of E. faecalis, associated with resistance to fluoroquinolones. They detected one strain with a substitution in parC but not in gyrA. For this strain the MIC was between the MICs for those with no mutations and those with simultaneous mutations in both gyrA and parC; consequently they suggested that parC might be the primary target for quinolones as in other gram-positive bacteria such as S. pneumoniae and S. aureus (16, 17). In a previous study, Pan and Fisher (20) showed that the quinolone primary target can differ depending on the structure of the compound. They demonstrated that parC is the primary target for ciprofloxacin, whereas gyrA is the primary target for sparfloxacin in laboratory selected mutant strains of S. pneumoniae. However, in the present study we could not determine the quinolone primary target, since we found no isolates with mutations in only one of the genes. For E. faecalis and S. pneumoniae strains with substitutions only in either parC or gyrA, the MICs of at least one of the quinolones studied were eightfold higher or more (14, 20). For the low-level resistant strain in our study the MICs of quinolones were two- to fourfold higher than that for the type strain, and the strain may carry mutations in the other subunits of gyrase and topoisomerase IV or efflux system.

Nucleotide sequence accession numbers. The gyrA and parC partial sequences of E. faecium appear in GenBank under accession no. AF060881 and AB017811, respectively.


    FOOTNOTES

* Corresponding author. Mailing address: Division of Clinical and Oral Bacteriology, Huddinge Hospital F82, S-14186 Huddinge, Sweden. Phone: 46-8-5858 7841. Fax: 46-8-711 3918. E-mail: bengt.wretlind{at}impi.ki.se.


    REFERENCES
Top
Abstract
Text
References

1. Bonilla, H. F., L. T. Zarins, S. F. Bradley, and C. A. Kauffman. 1996. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin. Diagn. Microbiol. Infect. Dis. 26:17-21[Medline].
2. Clark, N. C., R. C. Cooksey, B. C. Hill, J. M. Swenson, and F. C. Tenover. 1993. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob. Agents Chemother. 37:2311-2317[Abstract/Free Full Text].
3. Cullen, M. E., A. W. Wyke, R. Kuroda, and L. M. Fisher. 1989. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob. Agents Chemother. 33:886-894[Abstract/Free Full Text].
4. Ericsson, H. M., and J. C. Sherris. 1971. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol. Microbiol. Scand. Sect. B 217(Suppl.):1-90.
5. Everett, M. J., Y. F. Jin, V. Ricci, and L. J. V. Piddock. 1996. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40:2380-2386[Abstract].
6. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653[Medline].
7. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558[Abstract].
8. Guillemin, I., E. Cambau, and V. Jarlier. 1995. Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones. Antimicrob. Agents Chemother. 39:2145-2149[Abstract].
9. Heisig, P., H. Schedletzky, and H. Falkenstein-Paul. 1993. Mutation in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob. Agents Chemother. 37:696-701[Abstract/Free Full Text].
10. Herrera-Insúa, I., K. Jacques-Palaz, B. E. Murray, and R. M. Rakita. 1996. Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium. Antimicrob. Agents Chemother. 40:886-890[Abstract].
11. Jalal, S., and B. Wretlind. 1998. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb. Drug Resist. 4:257-261. [Medline]
12. Jones, R. N., D. M. Johnson, D. J. Biedenbach, and S. A. Marshall. 1995. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates. Diagn. Microbiol. Infect. Dis. 23:123-127[Medline].
13. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094[Abstract/Free Full Text].
14. Kanematsu, E., T. Deguchi, M. Yasuda, T. Kawamura, Y. Nishino, and Y. Kawada. 1998. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob. Agents Chemother. 42:433-435[Abstract/Free Full Text].
15. Korten, V., W. M. Huang, and B. E. Murray. 1994. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob. Agents Chemother. 38:2091-2094[Abstract/Free Full Text].
16. Muñoz, R., and A. G. de la Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257[Abstract].
17. Ng, E. Y., M. Trucksis, and D. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888[Abstract].
18. Oram, M., and L. M. Fisher. 1991. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob. Agents Chemother. 35:387-389[Abstract/Free Full Text].
19. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1994. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326[Abstract].
20. Pan, X.-S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474[Abstract].
21. Patterson, J. E., A. H. Sweeney, M. Simms, N. Carley, R. Mangi, J. Sabetta, and R. W. Lyons. 1995. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine 74:191-200[Medline].
22. Piddock, L. J. 1991. Mechanism of quinolone uptake into bacterial cells. J. Antimicrob. Chemother. 27:399-403[Free Full Text].
23. Piddock, L. J., D. J. Griggs, M. C. Hall, and Y. F. Jin. 1993. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob. Agents Chemother. 37:662-666[Abstract/Free Full Text].
24. Pitcher, D. G., N. A. Saunders, and R. J. Owen. 1989. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett. Appl. Microbiol. 8:151-156.
25. Takenouchi, T., C. Ishii, M. Sugawara, Y. Tokue, and S. Ohya. 1995. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob. Agents Chemother. 39:1414-1418[Abstract].
26. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510[Abstract].
27. Truong, Q. C., J.-C. Nguyen Van, D. Shlaes, L. Gutmann, and N. J. Moreau. 1997. A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics. Antimicrob. Agents Chemother. 41:85-90[Abstract].
28. Waters, B., and J. Davies. 1997. Amino acid variation in the GyrA subunit of bacteria potentially associated with natural resistance to fluoroquinolone antibiotics. Antimicrob. Agents Chemother. 41:2766-2769[Abstract].
29. Yoshida, H., M. Nakamura, M. Bogaki, and S. Nakamura. 1990. Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:1273-1275[Abstract/Free Full Text].
30. Yoshida, H., M. Nakamura, M. Bogaki, H. Ito, T. Kojima, H. Hattori, and S. Nakamura. 1993. Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob. Agents Chemother. 37:839-845[Abstract/Free Full Text].
31. Yoshida, H., M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno. 1990. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 172:6942-6949[Abstract/Free Full Text].

Antimicrobial Agents and Chemotherapy, April 1999, p. 947-949, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Escudero, J. A., San Millan, A., Catalan, A., de la Campa, A. G., Rivero, E., Lopez, G., Dominguez, L., Moreno, M. A., Gonzalez-Zorn, B. (2007). First Characterization of Fluoroquinolone Resistance in Streptococcus suis. Antimicrob. Agents Chemother. 51: 777-782 [Abstract] [Full Text]  
  • Wickman, P. A., Black, J. A., Smith Moland, E., Thomson, K. S., Hanson, N. D. (2006). In vitro development of resistance to DX-619 and other quinolones in enterococci. J Antimicrob Chemother 58: 1268-1273 [Abstract] [Full Text]  
  • Oyamada, Y., Ito, H., Fujimoto, K., Asada, R., Niga, T., Okamoto, R., Inoue, M., Yamagishi, J.-i. (2006). Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J Med Microbiol 55: 729-736 [Abstract] [Full Text]  
  • Leavis, H. L., Willems, R. J. L., Top, J., Bonten, M. J. M. (2006). High-Level Ciprofloxacin Resistance from Point Mutations in gyrA and parC Confined to Global Hospital-Adapted Clonal Lineage CC17 of Enterococcus faecium.. J. Clin. Microbiol. 44: 1059-1064 [Abstract] [Full Text]  
  • Sultan, Z., Nahar, S., Wretlind, B., Lindback, E., Rahman, M. (2004). Comparison of Mismatch Amplification Mutation Assay with DNA Sequencing for Characterization of Fluoroquinolone Resistance in Neisseria gonorrhoeae. J. Clin. Microbiol. 42: 591-594 [Abstract] [Full Text]  
  • Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., Varon, E. (2003). In Vitro Activities of Garenoxacin (BMS-284756) against Streptococcus pneumoniae, Viridans Group Streptococci, and Enterococcus faecalis Compared to Those of Six Other Quinolones. Antimicrob. Agents Chemother. 47: 3542-3547 [Abstract] [Full Text]  
  • Hallgren, A., Saeedi, B., Nilsson, M., Monstein, H.-J., Isaksson, B., Hanberger, H., Nilsson, L. E. (2003). Genetic relatedness among Enterococcus faecalis with transposon-mediated high-level gentamicin resistance in Swedish intensive care units. J Antimicrob Chemother 52: 162-167 [Abstract] [Full Text]  
  • Oh, H., El Amin, N., Davies, T., Appelbaum, P. C., Edlund, C. (2001). gyrA Mutations Associated with Quinolone Resistance in Bacteroides fragilis Group Strains. Antimicrob. Agents Chemother. 45: 1977-1981 [Abstract] [Full Text]  
  • Boos, M., Mayer, S., Fischer, A., Köhrer, K., Scheuring, S., Heisig, P., Verhoef, J., Fluit, A. C., Schmitz, F.-J. (2001). In Vitro Development of Resistance to Six Quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 938-942 [Abstract] [Full Text]  
  • Stearne, L. E. T., Kooi, C., Goessens, W. H. F., Bakker-Woudenberg, I. A. J. M., Gyssens, I. C. (2001). In Vitro Activity of Trovafloxacin against Bacteroides fragilis in Mixed Culture with either Escherichia coli or a Vancomycin- Resistant Strain of Enterococcus faecium Determined by an Anaerobic Time-Kill Technique. Antimicrob. Agents Chemother. 45: 243-251 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by el Amin, N.
Right arrow Articles by Wretlind, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by el Amin, N.
Right arrow Articles by Wretlind, B.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»